drugset / Trial / NCT00326612

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

NCT00326612

RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.

Timeline

Start
2006-06
Primary completion
2008-12
Completion
2008-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diazepam Small molecule 0.3 mg/kg Rectal
Comparator Diazepam Small molecule 0.5 mg/kg Rectal
Comparator Midazolam Small molecule 0.2 mg/kg Intranasal

Indications